help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2005-0030
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Komm, B. S.
Right arrow Articles by Lyttle, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komm, B. S.
Right arrow Articles by Lyttle, C. R.
Endocrinology Vol. 146, No. 9 3999-4008
Copyright © 2005 by The Endocrine Society

Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity

Barry S. Komm, Yogendra P. Kharode, Peter V. N. Bodine, Heather A. Harris, Chris P. Miller and C. Richard Lyttle

Wyeth Research, Women’s Health Research Institute, Collegeville, Pennsylvania 19426

Address all correspondence and requests for reprints to: Barry Komm, 500 Arcola Road, Building N3252, Collegeville, Pennsylvania 19426. E-mail: kommb{at}wyeth.com.

We assessed the preclinical characteristics of a novel, stringently screened selective estrogen receptor modulator, bazedoxifene acetate, including its ability to bind to and activate estrogen receptors and promote increased bone mineral density and bone strength in rats, and the effects impacting the uterine endometrium, breast cancer cell proliferation, and central nervous system-associated vasomotor responses in an animal model. Bazedoxifene bound to estrogen receptor-{alpha} with an IC50 of 26 nM, an affinity similar to that of raloxifene. Bazedoxifene did not stimulate proliferation of MCF-7 cells but did inhibit 17ß-estradiol-induced proliferation with an IC50 of 0.19 nM. In an immature rat uterine model, bazedoxifene (0.5 and 5.0 mg/kg) was associated with less increase in uterine wet weight than either ethinyl estradiol (10 µg/kg) or raloxifene (0.5 and 5.0 mg/kg). Histological analysis revealed that coadministration of bazedoxifene also appeared to reduce raloxifene-stimulated endometrial luminal epithelial cell and myometrial cell hypertrophy. In ovariectomized rats, bazedoxifene was associated with significant increases in bone mineral density at 6 wk, compared with control, and better compressive strength of bone samples from the L4 vertebrae, compared with samples from ovariectomized animals. In the morphine-addicted rat model of vasomotor activity, bone-sparing doses of bazedoxifene alone were not associated with 17ß-estradiol inhibition of increased vasomotor activity. Bazedoxifene acetate represents a promising new treatment for osteoporosis, with a potential for less uterine and vasomotor effects than selective estrogen receptor modulators currently used in clinical practice. Controlled clinical trial data will be needed to confirm these effects.




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
A. Chandrasekaran, W. E. McKeand, P. Sullivan, W. DeMaio, R. Stoltz, and J. Scatina
Metabolic Disposition of [14C]Bazedoxifene in Healthy Postmenopausal Women
Drug Metab. Dispos., June 1, 2009; 37(6): 1219 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. J. Peano, J. S. Crabtree, B. S. Komm, R. C. Winneker, and H. A. Harris
Effects of Various Selective Estrogen Receptor Modulators with or without Conjugated Estrogens on Mouse Mammary Gland
Endocrinology, April 1, 2009; 150(4): 1897 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
B. S. Komm
Review Article: A New Approach to Menopausal Therapy: The Tissue Selective Estrogen Complex
Reproductive Sciences, December 1, 2008; 15(10): 984 - 992.
[Abstract] [PDF]

Home page
 EndocrinologyHome page
Y. Kharode, P. V. N. Bodine, C. P. Miller, C. R. Lyttle, and B. S. Komm
The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention
Endocrinology, December 1, 2008; 149(12): 6084 - 6091.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Y. Dai, M. J. Chalmers, J. Bruning, K. S. Bramlett, H. E. Osborne, C. Montrose-Rafizadeh, R. J. Barr, Y. Wang, M. Wang, T. P. Burris, et al.
Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method
PNAS, May 20, 2008; 105(20): 7171 - 7176.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. L Stump, K. W Kelley, and T. M Wensel
Bazedoxifene: A Third-Generation Selective Estrogen Receptor Modulator for Treatment of Postmenopausal Osteoporosis
Ann. Pharmacother., May 1, 2007; 41(5): 833 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. P. A. Barros, U. F. Machado, M. Warner, and J.-A. Gustafsson
Muscle GLUT4 regulation by estrogen receptors ERbeta and ER{alpha}
PNAS, January 31, 2006; 103(5): 1605 - 1608.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society